Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers

BACKGROUND: The benefit of immune checkpoint inhibitors (ICIs) in patients with leptomeningeal metastases (LMM) is unknown. METHODS: We undertook a phase II trial of pembrolizumab in patients with LMM from solid tumors. Eligible patients had radiologic/cytologic LMM and Eastern Cooperative Oncology...

Descripción completa

Detalles Bibliográficos
Autores principales: Naidoo, Jarushka, Schreck, Karisa C, Fu, Wei, Hu, Chen, Carvajal-Gonzalez, Alexander, Connolly, Roisin M, Santa-Maria, Cesar A, Lipson, Evan J, Holdhoff, Matthias, Forde, Patrick M, Douville, Christopher, Riemer, Joanne, Barnes, Amanda, Redmond, Kristin J, Kleinberg, Lawrence, Page, Brandi, Aygun, Nafi, Kinzler, Kenneth W, Papadopoulos, Nickolas, Bettegowda, Chetan, Venkatesan, Arun, Brahmer, Julie R, Grossman, Stuart A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359453/
https://www.ncbi.nlm.nih.gov/pubmed/34380662
http://dx.doi.org/10.1136/jitc-2021-002473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359453/
https://www.ncbi.nlm.nih.gov/pubmed/34380662
http://dx.doi.org/10.1136/jitc-2021-002473

Ejemplares similares